Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000362695
Ethics application status
Approved
Date submitted
29/08/2005
Date registered
12/09/2005
Date last updated
14/09/2007
Type of registration
Retrospectively registered
Titles & IDs
Public title
Antioxidants in bipolar disorder: A double blind randomised placebo controlled trial of n-acetyl cysteine.
Query!
Scientific title
Antioxidants in Bipolar Disorder: A double blind randomised placebo
controlled trial investigating n-acetyl cysteine effects on a range of
psychiatric rating scales
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bipolar disorder
457
0
Query!
Condition category
Condition code
Mental Health
533
533
0
0
Query!
Other mental health disorders
Query!
Neurological
534
534
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is a six month treatment study with a four to six week post-discontinuation visit. The trial involves 2g of n-acetyl cysteine per day in addition to the participants usual treatment.
Query!
Intervention code [1]
282
0
None
Query!
Comparator / control treatment
Placebo
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
614
0
Time to intervention for mood episode
Query!
Assessment method [1]
614
0
Query!
Timepoint [1]
614
0
When occurred
Query!
Secondary outcome [1]
1282
0
YMRS
Query!
Assessment method [1]
1282
0
Query!
Timepoint [1]
1282
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [2]
1283
0
BDRS
Query!
Assessment method [2]
1283
0
Query!
Timepoint [2]
1283
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [3]
1284
0
Q-LES-Q
Query!
Assessment method [3]
1284
0
Query!
Timepoint [3]
1284
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [4]
1285
0
Slice/life
Query!
Assessment method [4]
1285
0
Query!
Timepoint [4]
1285
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [5]
1286
0
Life/rift
Query!
Assessment method [5]
1286
0
Query!
Timepoint [5]
1286
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [6]
1287
0
SOFAS
Query!
Assessment method [6]
1287
0
Query!
Timepoint [6]
1287
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [7]
1288
0
CGI
Query!
Assessment method [7]
1288
0
Query!
Timepoint [7]
1288
0
At each trial visit. (Total of nine visits).
Query!
Secondary outcome [8]
1289
0
GAF
Query!
Assessment method [8]
1289
0
Query!
Timepoint [8]
1289
0
At each trial visit. (Total of nine visits).
Query!
Eligibility
Key inclusion criteria
DSM-IV diagnosis of bipolar disorder (I, II or NOS), have had at least one mood episode within the last 12 months, have been on stable treatment for one month, have the capacity to consent and be on effective contraception.
Query!
Minimum age
Not stated
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Asthma, history of ulcers, respiritory insufficiency, any current systemic medical disorder, participants who are currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day and women pregnant or lactacting.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3 / Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/01/2004
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
592
0
Other
Query!
Name [1]
592
0
Research Funds
Query!
Address [1]
592
0
Victoria
Query!
Country [1]
592
0
Australia
Query!
Primary sponsor type
Other
Query!
Name
Research Funds
Query!
Address
Victoria, Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
481
0
Other
Query!
Name [1]
481
0
Mental Health Research Institute
Query!
Address [1]
481
0
Parkville, Melbourne, Australia
Query!
Country [1]
481
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
1681
0
Barwon Health
Query!
Ethics committee address [1]
1681
0
Query!
Ethics committee country [1]
1681
0
Australia
Query!
Date submitted for ethics approval [1]
1681
0
Query!
Approval date [1]
1681
0
Query!
Ethics approval number [1]
1681
0
Query!
Ethics committee name [2]
1682
0
Bendigo Health Care Group
Query!
Ethics committee address [2]
1682
0
Query!
Ethics committee country [2]
1682
0
Australia
Query!
Date submitted for ethics approval [2]
1682
0
Query!
Approval date [2]
1682
0
Query!
Ethics approval number [2]
1682
0
Query!
Ethics committee name [3]
1683
0
South West Area Mental Health Service (Werribee)
Query!
Ethics committee address [3]
1683
0
Query!
Ethics committee country [3]
1683
0
Australia
Query!
Date submitted for ethics approval [3]
1683
0
Query!
Approval date [3]
1683
0
Query!
Ethics approval number [3]
1683
0
Query!
Summary
Brief summary
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35613
0
Query!
Address
35613
0
Query!
Country
35613
0
Query!
Phone
35613
0
Query!
Fax
35613
0
Query!
Email
35613
0
Query!
Contact person for public queries
Name
9471
0
Ms. Olivia Dean
Query!
Address
9471
0
The Geelong Hospital
Kitchener House
PO Box 281
Geelong VIC 3220
Query!
Country
9471
0
Australia
Query!
Phone
9471
0
+61 3 93892973
Query!
Fax
9471
0
Query!
Email
9471
0
[email protected]
Query!
Contact person for scientific queries
Name
399
0
Prof. Michael Berk
Query!
Address
399
0
The Geelong Hospital
Kitchener House
PO Box 281
Geelong VIC 3220
Query!
Country
399
0
Australia
Query!
Phone
399
0
+61 3 52603154
Query!
Fax
399
0
Query!
Email
399
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF